Plain-English translation of NCT06905288 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a real-world study looking at how well works for people with ankylosing spondylitis (a type of spine arthritis) in Korea. is a newer biologic medication that helps calm the inflammation causing your symptoms. The study wants to see if this treatment is effective for younger patients who are being treated with a biologic drug for the first time.
Ankylosing spondylitis can be very painful and limiting, especially for young adults. While this medication has been approved, doctors want real-world data showing how well it actually works for patients like you in everyday life, so they can better understand who benefits most.
You likely qualify if…
You likely don't qualify if…
You would take as prescribed by your doctor for about 7 months. You would visit the clinic three times: at the start, after 16 weeks, and after 28 weeks. At each visit, your doctors will ask about your symptoms and check how well the medication is working for your spine arthritis. This is not an interventional trial where you're assigned a new drug—you'll be taking medication that's already approved and available to you.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
South Korea
Sponsor
Novartis Pharmaceuticals
Enrollment target
~70 participants
Started
April 2025
Primary completion
December 2026
Age range
18 Years – 40 Years
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Novartis Pharmaceuticals, MD
Novartis Pharmaceuticals
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.